CA3123510A1 — Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
Assigned to Novartis AG · Expires 2020-06-25 · 6y expired
What this patent protects
The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a CKD4/6 inhibitor, particularly ribociclib, particularly for use in the treatment of a proliferative disease, pre…
USPTO Abstract
The present invention relates to a pharmaceutical combination comprising (a) a Raf inhibitor as defined herein, or a pharmaceutically acceptable salt thereof and (b) a CKD4/6 inhibitor, particularly ribociclib, particularly for use in the treatment of a proliferative disease, preferably melanoma or pancreatic ductal adenocarcinoma.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.